Emerging pharmacological therapies for ARDS: COVID-19 and beyond

[1]  R. Horton,et al.  The Wakley–Wu Lien Teh Prize Essay 2020: Chinese health workers' experiences during the COVID-19 pandemic , 2020, The Lancet.

[2]  F. Weber,et al.  Inhibition of SARS–CoV-2 by type I and type III interferons , 2020, The Journal of Biological Chemistry.

[3]  Xinchun Chen,et al.  Viral dynamics of SARS-CoV-2 in saliva from infected patients , 2020, Journal of Infection.

[4]  T. Walsh,et al.  Mobile oxazolidinone/phenicol resistance gene optrA in chicken Clostridium perfringens. , 2020, The Journal of antimicrobial chemotherapy.

[5]  K. To,et al.  SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series , 2020, The Lancet Infectious Diseases.

[6]  Patrick W. Johnson,et al.  Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. , 2020, The Journal of clinical investigation.

[7]  G. Koh,et al.  Faculty Opinions recommendation of Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. , 2020 .

[8]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[9]  Amit N. Patel,et al.  RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis , 2020, The Lancet.

[10]  D. Brainard,et al.  Compassionate Use of Remdesivir in Covid-19. Reply. , 2020, The New England journal of medicine.

[11]  Kwok-Hung Chan,et al.  Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial , 2020, The Lancet.

[12]  J. Laffey,et al.  Can Nebulised Heparin Reduce Time to Extubation in SARS CoV 2 The CHARTER Study Protocol , 2020, medRxiv.

[13]  P. Zimetbaum,et al.  Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.

[14]  Xiaohu Zheng,et al.  Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[15]  Changyu Shen,et al.  Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs. , 2020, JAMA.

[16]  Yi Wang,et al.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.

[17]  Baoju Wang,et al.  A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia , 2020, Signal Transduction and Targeted Therapy.

[18]  André Machado Siqueira,et al.  Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.

[19]  M. Barbagallo,et al.  Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature , 2020, Frontiers in Medicine.

[20]  E. Nicastri,et al.  Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact , 2020, Journal of Infection.

[21]  Zhen Zhu,et al.  Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19 , 2020, Journal of Infection.

[22]  Erwan L'Her,et al.  Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.

[23]  Y. Yazdanpanah,et al.  Type 1 interferons as a potential treatment against COVID-19 , 2020, Antiviral Research.

[24]  S. Pastores,et al.  Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019 , 2020, Critical care explorations.

[25]  Dengju Li,et al.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.

[26]  Jing Yuan,et al.  Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. , 2020, JAMA.

[27]  Bo Chen,et al.  Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial , 2020, medRxiv.

[28]  D. Raoult,et al.  Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial , 2020, medRxiv.

[29]  Q. Tong,et al.  COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression , 2020, The Journal of antimicrobial chemotherapy.

[30]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[31]  Wu Zhong,et al.  Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study , 2020, Engineering.

[32]  Fabian J Theis,et al.  SARS-CoV-2 Receptor ACE2 is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Enriched in Specific Cell Subsets Across Tissues , 2020, SSRN Electronic Journal.

[33]  Mel S. Lee,et al.  Human Umbilical Cord-Derived Mesenchymal Stem Cells for Acute Respiratory Distress Syndrome , 2020, Critical care medicine.

[34]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[35]  W. Kuebler,et al.  TRPV4—A Missing Link Between Mechanosensation and Immunity , 2020, Frontiers in Immunology.

[36]  C. Caruso,et al.  Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia , 2020, Aging and disease.

[37]  Vineet D. Menachery,et al.  Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV , 2020, Journal of Virology.

[38]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[39]  J. Vincent,et al.  Effect of Intravenous Interferon β-1a on Death and Days Free From Mechanical Ventilation Among Patients With Moderate to Severe Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. , 2020, JAMA.

[40]  Y. Hu,et al.  On the use of corticosteroids for 2019-nCoV pneumonia , 2020, The Lancet.

[41]  J. González-Martín,et al.  Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. , 2020, The Lancet. Respiratory medicine.

[42]  J. Laffey,et al.  Cytokine pre-activation of cryopreserved xenogeneic-free human mesenchymal stromal cells enhances resolution and repair following ventilator-induced lung injury potentially via a KGF-dependent mechanism , 2020, Intensive Care Medicine Experimental.

[43]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[44]  A. Phelan,et al.  Baricitinib as potential treatment for 2019-nCoV acute respiratory disease , 2020, The Lancet.

[45]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[46]  B. Southern,et al.  TRPV4 Protects the Lung from Bacterial Pneumonia via MAPK Molecular Pathway Switching , 2020, The Journal of Immunology.

[47]  J. Luban.  SARS-CoV-2 , 2020 .

[48]  A. Abdelaal Ahmed Mahmoud,et al.  Streptokinase Versus Unfractionated Heparin Nebulization in Patients With Severe Acute Respiratory Distress Syndrome (ARDS): A Randomized Controlled Trial With Observational Controls. , 2020, Journal of cardiothoracic and vascular anesthesia.

[49]  A. Artigas,et al.  Effects of nebulized antithrombin and heparin on inflammatory and coagulation alterations in an acute lung injury model in rats , 2019, Journal of thrombosis and haemostasis : JTH.

[50]  Hui Li,et al.  Anti-IFN-γ therapy alleviates acute lung injury induced by severe influenza A (H1N1) pdm09 infection in mice. , 2019, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[51]  G. Martin,et al.  Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. , 2019, JAMA.

[52]  B. Souweine,et al.  Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial. , 2019, The Lancet. Respiratory medicine.

[53]  C. Putensen,et al.  Tetracycline alleviates acute lung injury by inhibition of NLRP3 inflammasome , 2019, Acute critical care.

[54]  Q. Lian,et al.  Lipoxin A4 ameliorates lipopolysaccharide-induced lung injury through stimulating epithelial proliferation, reducing epithelial cell apoptosis and inhibits epithelial–mesenchymal transition , 2019, Respiratory Research.

[55]  Jing Gong,et al.  Alpha 1-antitrypsin for treating ventilator-associated lung injury in acute respiratory distress syndrome rats , 2019, Experimental lung research.

[56]  P. Tuinman,et al.  Antithrombin plus alpha-1 protease inhibitor does not affect coagulation and inflammation in two murine models of acute lung injury , 2019, Intensive Care Medicine Experimental.

[57]  M. Exline,et al.  Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. , 2019, The Lancet. Respiratory medicine.

[58]  M. Shankar-Hari,et al.  Population enrichment for critical care trials: phenotypes and differential outcomes. , 2019, Current opinion in critical care.

[59]  C. Piantadosi,et al.  A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS. , 2018, JCI insight.

[60]  M. Gladwin,et al.  Haptoglobin improves shock, lung injury, and survival in canine pneumonia. , 2018, JCI insight.

[61]  V. Sapin,et al.  Inhibition of the Receptor for Advanced Glycation End-Products in Acute Respiratory Distress Syndrome: A Randomised Laboratory Trial in Piglets , 2018, Scientific Reports.

[62]  J. Laffey,et al.  Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. , 2018, The Lancet. Respiratory medicine.

[63]  J. Laffey,et al.  Negative trials in critical care: why most research is probably wrong. , 2018, The Lancet. Respiratory medicine.

[64]  Qian Li,et al.  PIRFENIDONE AMELIORATES LIPOPOLYSACCHARIDE‐INDUCED PULMONARYINFLAMMATION AND FIBROSIS BY BLOCKING NLRP3 INFLAMMASOME ACTIVATION , 2018, Molecular immunology.

[65]  Yong Jiang,et al.  Effects of ulinastatin combined with mechanical ventilation on oxygen metabolism, inflammation and stress response and antioxidant capacity of ARDS , 2018, Experimental and therapeutic medicine.

[66]  B. Souweine,et al.  Receptor for advanced glycation end-products and ARDS prediction: a multicentre observational study , 2018, Scientific Reports.

[67]  M. Hind,et al.  Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury , 2018, Thorax.

[68]  Rajaa Al-Raddadi,et al.  Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome , 2017, American journal of respiratory and critical care medicine.

[69]  Akram Khan,et al.  A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome , 2017, Critical Care.

[70]  V. Sapin,et al.  RAGE inhibition reduces acute lung injury in mice , 2017, Scientific Reports.

[71]  Y. Furuta,et al.  Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase , 2017, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[72]  G. Martin,et al.  Plasma Neutrophil Elastase and Elafin as Prognostic Biomarker for Acute Respiratory Distress Syndrome: A Multicenter Survival and Longitudinal Prospective Observation Study , 2017, Shock.

[73]  R. Lucas,et al.  Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial , 2017, Critical Care.

[74]  Tomohiro Murata,et al.  Tocilizumab for uncontrollable systemic inflammatory response syndrome complicating adult-onset Still disease , 2017, Medicine.

[75]  Lisa E. Gralinski,et al.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.

[76]  B. Southern,et al.  The Role of Transient Receptor Potential Vanilloid 4 in Pulmonary Inflammatory Diseases , 2017, Front. Immunol..

[77]  T. van der Poll,et al.  Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis , 2017, Thorax.

[78]  Juan Manuel Barja López,et al.  Benefit of Tocilizumab Therapy for Adult-Onset Still Disease Complicated With Acute Respiratory Distress Syndrome. , 2016, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[79]  D. Thickett,et al.  Lipoxin A4 promotes lung epithelial repair whilst inhibiting fibroblast proliferation , 2016, ERJ Open Research.

[80]  William A. Lee,et al.  Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys , 2016, Nature.

[81]  Anders Larsson,et al.  Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. , 2016, JAMA.

[82]  Richard L. Amdur,et al.  Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial* , 2016, Critical care medicine.

[83]  B. Dixon,et al.  A Trial of Nebulised Heparin to Limit Lung Injury following Cardiac Surgery , 2016, Anaesthesia and intensive care.

[84]  E. Letsiou,et al.  Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury. , 2015, American journal of physiology. Lung cellular and molecular physiology.

[85]  R. Stephens,et al.  The tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice , 2015, Physiological reports.

[86]  C. Teunissen,et al.  Inhaled carbon monoxide protects time-dependently from loss of hypoxic pulmonary vasoconstriction in endotoxemic mice , 2015, Respiratory Research.

[87]  A. May,et al.  A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome , 2015, Critical care medicine.

[88]  J. Laffey,et al.  Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E. coli in the rat , 2015, Thorax.

[89]  J. Laffey,et al.  Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental Acute Respiratory Distress Syndrome , 2015, Intensive Care Medicine Experimental.

[90]  B. Thompson,et al.  Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. , 2015, The Lancet. Respiratory medicine.

[91]  D. McAuley,et al.  A functional variant of elafin with improved anti-inflammatory activity for pulmonary inflammation. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[92]  W. Kuebler,et al.  TRPV4: an exciting new target to promote alveolocapillary barrier function. , 2014, American journal of physiology. Lung cellular and molecular physiology.

[93]  S. Matalon,et al.  TRPV4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injury. , 2014, American journal of physiology. Lung cellular and molecular physiology.

[94]  P. Ward,et al.  Critical Role for the NLRP3 Inflammasome during Acute Lung Injury , 2014, The Journal of Immunology.

[95]  Wei Wei,et al.  Anti-Inflammatory Effect of Thalidomide on H1N1 Influenza Virus-Induced Pulmonary Injury in Mice , 2014, Inflammation.

[96]  Thomas Walther,et al.  Angiotensin-(1–7) Protects From Experimental Acute Lung Injury , 2013, Critical care medicine.

[97]  Z. Memish,et al.  Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy , 2013, International Journal of Infectious Diseases.

[98]  K. Yuen,et al.  Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. , 2013, Chest.

[99]  G. Bernard,et al.  Low plasma citrulline levels are associated with acute respiratory distress syndrome in patients with severe sepsis , 2013, Critical Care.

[100]  Chengyu Jiang,et al.  Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model , 2012, Cell Research.

[101]  D. McAuley,et al.  Proteolytic cleavage of elafin by 20S proteasome may contribute to inflammation in acute lung injury , 2012, Thorax.

[102]  Stephanie R. Kuzenko,et al.  The adenosine 2A receptor agonist GW328267C improves lung function after acute lung injury in rats. , 2012, American Journal of Physiology - Lung cellular and Molecular Physiology.

[103]  Patrick M Liu,et al.  A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome , 2012, BMC Pulmonary Medicine.

[104]  B. Dixon,et al.  Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial , 2010, Critical care.

[105]  W. Liedtke,et al.  TRPV4 channels augment macrophage activation and ventilator-induced lung injury. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[106]  Vijay Kumar,et al.  Thalidomide treatment modulates macrophage pro-inflammatory function and cytokine levels in Klebsiella pneumoniae B5055 induced pneumonia in BALB/c mice. , 2010, International immunopharmacology.

[107]  J. Bastarache,et al.  Procoagulant alveolar microparticles in the lungs of patients with acute respiratory distress syndrome. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[108]  Arthur S Slutsky,et al.  Protective effects of adenosine A2A receptor agonist in ventilator-induced lung injury in rats , 2009, Critical care medicine.

[109]  R. Crystal,et al.  Genetic delivery of bevacizumab to suppress vascular endothelial growth factor-induced high-permeability pulmonary edema. , 2009, Human gene therapy.

[110]  S. Ryter,et al.  Heme oxygenase/carbon monoxide signaling pathways: Regulation and functional significance , 2002, Molecular and Cellular Biochemistry.

[111]  N. McElvaney,et al.  Local impairment of anti-neutrophil elastase capacity in community-acquired pneumonia. , 2003, The Journal of infectious diseases.

[112]  F. Berger,et al.  Haptoglobin reduces lung injury associated with exposure to blood. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[113]  S. Opal,et al.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. , 1997, Critical care medicine.

[114]  B. Dijkmans,et al.  Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. , 1997, The Journal of rheumatology.

[115]  W. Knaus,et al.  Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group. , 1996, Critical care medicine.

[116]  R. F. Johnston,et al.  Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial , 1994 .

[117]  S. Opal,et al.  Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. , 1994, JAMA.

[118]  T L Petty,et al.  Acute respiratory distress in adults. , 1967, Lancet.